Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China

“…Compared with chemotherapy, pembrolizumab has been indicated as cost‐effectiveness for treating Swiss NSCLC patients, but unlikely to be cost‐effectiveness for Singaporean NSCLC patients. Moreover, nivolumab and atezolizumab also showed similar results in comparison with chemotherapy in cost‐effectiveness studies 15,25–27 . Although the efficacy of PD‐1/PD‐L1 inhibitors is significantly greater than that of chemotherapy, their cost is currently higher, and does not provide benefits for some patients.…”

“…Moreover, nivolumab and atezolizumab also showed similar results in comparison with chemotherapy in cost‐effectiveness studies. 15 , 25 , 26 , 27 Although the efficacy of PD‐1/PD‐L1 inhibitors is significantly greater than that of chemotherapy, their cost is currently higher, and does not provide benefits for some patients. High drug costs have become the main driver for limiting widespread immunotherapy use for cancer and bring great burdens on both the patients themselves and society as a whole.…”

Cost‐effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore

“…Base‐case HSUVs were obtained from a published Canadian quality of life study in patients with HR+, HER2− ABC where the EQ‐5D questionnaire was used to derive utilities. EQ‐5D is a preferred instrument for utility elicitation by several HTA agencies 21,22 and has often been used in breast cancer 29 and local CEAs 30‐32 . As a generic measure, EQ‐5D is better suited for health policy decisions and funding allocation as it allows for comparisons across disease areas and health technologies.…”

“…Consequently, despite the statistically significant OS 21,22 and has often been used in breast cancer 29 and local CEAs. [30][31][32] As a generic measure, EQ-5D is better suited for health policy decisions and funding allocation as it allows for comparisons across disease areas and health technologies. As country settings may affect HSUVs, a scenario analysis was conducted based on local…”

The role of immunotherapy in fusion-driven lung cancer

“…Collectively, this means there is a significant cohort of fusiondriven NSCLC patients, that are likely to be exposed to immune checkpoint inhibition whether as first-line therapy or in the resistant setting. Recent cost-effectiveness analyses have questioned the value of immune checkpoint inhibition in various diverse healthcare settings [33][34][35]. In a cohort of patients in whom there is limited efficacy, exposing patients to ineffective and expensive therapies that are not without toxicity is also of concern.…”